Plinabulin
CAS: 714272-27-2
Ref. 3D-FP179112
1g | Discontinued | ||
2g | Discontinued | ||
5g | Discontinued | ||
250mg | Discontinued | ||
500mg | Discontinued |
Product Information
- (3Z,6Z)-3-[(5-tert-Butyl-1H-imidazol-4-yl)methylene]-6-(phenylmethylene)-2,5-piperazinedione
- (3Z,6Z)-3-[[5-(1,1-Dimethylethyl)-1H-imidazol-4-yl]methylene]-6-(phenylmethylene)-2,5-piperazinedione
- 2,5-Piperazinedione, 3-[[5-(1,1-dimethylethyl)-1H-imidazol-4-yl]methylene]-6-(phenylmethylene)-, (3Z,6Z)-
- Bpi 2358
- Npi 2358
Plinabulin is a drug that inhibits the progress of cancer by inhibiting angiogenesis. Plinabulin binds to a platinum-based chemotherapy called cisplatin and prevents its release into the body, thus inhibiting its cytotoxicity. Plinabulin also has anti-angiogenic effects, which are due to its ability to inhibit the activation of cell signaling pathways, such as those mediated by colony-stimulating factor. Plinabulin's cytotoxicity has been demonstrated in vivo using a skin cancer model, where it showed significant cytotoxicity against tumor cells without affecting nearby healthy cells. This drug also has structural biology implications because it binds with high affinity to human macrophages and can be used for chemical biology studies.